Hansen delivers Q2 revenues
Hansen Medical, a Mountain View, Calif.-based developer of medical robotics for positioning, manipulation and control of catheters and catheter-based technologies, reported its first period as a revenue-generating operation for its fiscal 2007 second quarter (end-June 30).
The company said that total revenue for the period was $2.4 million. During the quarter, the company recorded revenue on the sale of four Sensei Robotic Catheter Systems and initial shipments of Artisan Control Catheters and at an average system selling price of $593,000.
The net loss for the second quarter was $7.9 million, compared with a net loss of $6.3 million for the same period last year.
Hansen said it recently received U.S. Food and Drug Administration (FDA) clearance for commercialization of its Sensei Robotic Catheter System and Artisan Control Catheter in the United States for use during electrophysiology (EP) procedures. This was followed by receipt of CE Mark approval in the European Union (EU) for the Artisan Control Catheter, enabling the company to begin marketing its products in Europe, also for use during EP procedures.
The company said that total revenue for the period was $2.4 million. During the quarter, the company recorded revenue on the sale of four Sensei Robotic Catheter Systems and initial shipments of Artisan Control Catheters and at an average system selling price of $593,000.
The net loss for the second quarter was $7.9 million, compared with a net loss of $6.3 million for the same period last year.
Hansen said it recently received U.S. Food and Drug Administration (FDA) clearance for commercialization of its Sensei Robotic Catheter System and Artisan Control Catheter in the United States for use during electrophysiology (EP) procedures. This was followed by receipt of CE Mark approval in the European Union (EU) for the Artisan Control Catheter, enabling the company to begin marketing its products in Europe, also for use during EP procedures.